Literature DB >> 14723376

Atovaquone/proguanil resistance in Africa: a case report.

Kim P David1, Michael Alifrangis, Ali Salanti, Lasse S Vestergaard, Anita Rønn, I B Bygbjerg.   

Abstract

The Atovaquone/proguanil combination has quickly been established as an effective chemoprophylaxis for travellers to areas with chloroquineresistant Plasmodium falciparum malaria. We describe the molecular cause of the first reported case of primary Atovaquone/proguanil resistance observed in our department in a Plasmodium falciparum infected traveller returning from West Africa, and link our findings to other reports of resistance.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14723376

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  17 in total

1.  First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.

Authors:  Helene Savini; Hervé Bogreau; Lionel Bertaux; Housem Bouchiba; Philippe Kraemer; Daniel Parzy; Eric Garnotel; Christophe Rogier; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

2.  [Malaria--current diagnosis and therapy].

Authors:  Isabel Barreto Miranda; Thomas Löscher
Journal:  Med Klin (Munich)       Date:  2009-07-15

3.  Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Authors:  Luicer A Ingasia; Hoseah M Akala; Mabel O Imbuga; Benjamin H Opot; Fredrick L Eyase; Jacob D Johnson; Wallace D Bulimo; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Menoctone Resistance in Malaria Parasites Is Conferred by M133I Mutations in Cytochrome b That Are Transmissible through Mosquitoes.

Authors:  Lynn D Blake; Myles E Johnson; Sasha V Siegel; Adonis McQueen; Iredia D Iyamu; Abdul Kadar Shaikh; Michael W Shultis; Roman Manetsch; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Pharmacodynamic interaction between atovaquone and other antimalarial compounds against Plasmodium falciparum in vitro.

Authors:  Carola Lütgendorf; Chaiporn Rojanawatsirivet; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

6.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

7.  Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine.

Authors:  Suci Nuralitha; Josephine E Siregar; Din Syafruddin; Jessica Roelands; Jan Verhoef; Andy I M Hoepelman; Sangkot Marzuki
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

8.  Synergistic interaction between atovaquone and retinol in Plasmodium falciparum in vitro.

Authors:  Bettina Exner; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 2.275

9.  In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.

Authors:  Rommanee Khositnithikul; Peerapan Tan-Ariya; Mathirut Mungthin
Journal:  Malar J       Date:  2008-01-28       Impact factor: 2.979

10.  Distinction of Plasmodium falciparum recrudescence and re-infection by MSP2 genotyping: a caution about unstandardized classification criteria.

Authors:  Petrica Rouse; Mtawa Ap Mkulama; Philip E Thuma; Sungano Mharakurwa
Journal:  Malar J       Date:  2008-09-23       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.